Axial Spondyloarthritis Resources

12/03/2025

This study analysed information from IMAS - the International Map of Axial Spondyloarthritis. In a nutshell, the global delay to diagnosis is 7.4 years with large regional differences. What causes a longer delay to diagnosis? Younger age at symptom onset, female gender, diagnosis made by a rheumatologist, greater number of HCPs seen before diagnosis and history of uveitis were the parameters associated with a longer diagnostic delay in axSpA patients.

In this global sample of axSpA patients the mean diagnostic delay was 7.4 years, and showed significant differences across regions. Younger age at symptom onset, female gender, diagnosis made by a rheumatologist, greater number of HCPs seen before diagnosis and history of uveitis were the parameters...

11/28/2025

Would Josylin Nyanhete and Ubaz Dar please contact me to receive copies of Dr. Khan's book. Thank you.

11/28/2025

We have winners! As promised, I am sending two copies of Dr. Khan's book to two names drawn randomly from the first 100 Followers of this page. The winners are Josylin Nyanhete and Ubaz Dar. Thank you for following this page. Please share it with family, friends and other axSpA patients and their caregivers. Also, I recommend all patients obtain a copy of the pictured book (available from Amazon). It's written for patients and is an interesting and informative read and reference.

11/24/2025

Look at the time lines for Diagnosis. This is something to strive for. We are not there yet!

How can care of axSpA patients be improved? Here are some suggested targets for diagnosis, treatment and management of axSpA in clinical practice based on recent publications.

11/24/2025

Does having the HLA-B*27 gene mean you have axSpA? NO, it is not a definitive test, but it does help with making a diagnosis.

In this episode, we explore the truth behind the HLA-B27 gene and its connection to ankylosing spondylitis (AS). We break down common misconceptions, especia...

11/22/2025

The biggest complaints of patients with inflammatory arthritis, including axSpA, are pain and fatigue. There's a new way of looking at chronic pain:

Persistent pain remains a major challenge in inflammatory arthritis, even when joint inflammation is well controlled. Pain and associated symptoms such as fatigue cannot be explained by peripheral in...

11/21/2025

While not directly related to axSpA, I offer this video as a sort of public service announcement. If you are thinking of starting on supplements or someone is encouraging you to do so, have a very hard think about why? What are they supposed to do? Is there any evidence for their safety and efficacy? What is the proper dosage? Will they interfere with your medications? https://www.facebook.com/share/v/1B5u7W5Ai5/

11/19/2025

Is there something in the gut (likely not klebsiella) that may cause or cure axial spondyloarthritis? This case study on one person looks at treatment with FMT - F***l Microbiota Transplant - that seemed to work. Refactory AS is radiographic axSpA that hasn't responded to conventional treatments. https://pmc.ncbi.nlm.nih.gov/articles/PMC9996308/?fbclid=IwY2xjawOK0QlleHRuA2FlbQIxMQBzcnRjBmFwcF9pZBAyMjIwMzkxNzg4MjAwODkyAAEedhBsBwPRXkXMoBLtu3uNooIbrZjqb_G-8EnmXOIEosko7rFw6n1JKe_z8n4_aem_NDJ3HP30S9qJT8L9FMTxDQ

Ankylosing spondylitis (AS) is the prototype of a group of systemic inflammatory diseases referred to as spondyloarthritis. Comorbid inflammatory bowel disease and changed gut microbiota in AS have attracted attention to the influence of gut–joint ...

11/14/2025

A very timely review of Novel therapies for axial spondyloarthritis and future directions, illustrating the many treatment options now available compared with the 1990s, when biologics were not yet available.

10/28/2025

Big news released at the American College of Rheumatology Convergence Conference this week. New ASAS SPARTAN Classification Criteria for axSpA, with better sensitivity and specificity: https://www.facebook.com/share/16NEo1Z1qp/

🆕 Big update for : revised ASAS & SPARTAN classification criteria presented today in the Plenary!
Happening today in the Plenary session!
👉 https://acrabstracts.org/abstract/the-assessments-in-spondyloarthritis-international-society-asas-and-spondyloarthritis-research-and-treatment-network-spartan-revised-classification-criteria-for-axial-spondyloarthritis-developmen/

10/08/2025

The more standardization the better.

📢 New! Official ASAS recommendations for reporting axSpA in clinical trials. Open access
👉 https://ard.eular.org/article/S0003-4967(25)04287-6/fulltext

09/08/2025

All about uveitis and biologics: https://www.facebook.com/share/1GWeNHq7e2/

New publication from ASAS-COMOSPA study.
Acute anterior uveítis is the most common extra-musculoskeletal manifestation in SpA.
💊 Biologic therapies, especially monoclonal TNF-inhibitors, have been shown to be effective in uveítis treatment.
👁️ It was found a lower frequency ofuveitis development in SpA patients after the year 2000, the period in which biologics were introduced as SpA treatment.